We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+15.75%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.54B
AUM Growth
+$40.4M
Cap. Flow
-$337M
Cap. Flow %
-21.88%
Top 10 Hldgs %
46.87%
Holding
259
New
90
Increased
52
Reduced
41
Closed
65

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$25.6M
2
TMP icon
Tompkins Financial
TMP
+$13.1M
3
AGEN
Agenus
AGEN
+$6.13M
4
MNKD icon
MannKind Corp
MNKD
+$5.33M
5
MDVN
MEDIVATION, INC.
MDVN
+$3.71M

Top Sells

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$28.4M
2
ABBV icon
AbbVie
ABBV
+$14.7M
3
ZTS icon
Zoetis
ZTS
+$14.2M
4
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$11.5M
5
ARWR icon
Arrowhead Research
ARWR
+$8.75M

Sector Composition

Rank Sector Weight
1 Healthcare 10.49%
2 Financials 0.07%
3 Technology 0.07%
4 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
101
Madrigal Pharmaceuticals
MDGL
$12.4B
$1.58M 0.1%
7,170
+991
+16% +$211K
ACHV icon
102
PUT
Achieve Life Sciences
ACHV
$634M
$1.53M 0.1%
1
– –
ACHN
103
DELISTED
Achillion Pharmaceuticals
ACHN
$1.46M 0.1%
+484,879
New +$3.32M
ARNA
104
PUT
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.46M 0.09%
277
-663
-71% -$44.5K
VCEL icon
105
Vericel Corp
VCEL
$2.39B
$1.44M 0.09%
+259,461
New +$1.85M
TGTX icon
106
TG Therapeutics
TGTX
$8.4B
$1.4M 0.09%
+275,479
New +$1.68M
MRK icon
107
PUT
Merck
MRK
$326B
$1.4M 0.09%
307
– –
AZN icon
108
AstraZeneca
AZN
$267B
$1.38M 0.09%
+26,585
New +$1.34M
CASC
109
DELISTED
Cascadian Therapeutics, Inc.
CASC
$1.36M 0.09%
+109,933
New +$1.16M
UTHR icon
110
CALL
United Therapeutics
UTHR
$26.1B
$1.32M 0.09%
+168
New +$12.3K
AZN icon
111
CALL
AstraZeneca
AZN
$267B
$1.25M 0.08%
241
-4,588
-95% -$230K
EXAS
112
CALL
DELISTED
Exact Sciences
EXAS
$1.21M 0.08%
+1,025
New +$13.2K
UNXL
113
CALL
DELISTED
Uni-Pixel, Inc.
UNXL
$1.2M 0.08%
+677
New +$10.8K
AMRN
114
Amarin Corp
AMRN
$293M
$1.16M 0.08%
9,192
-3,372
-27% -$404K
CLDX icon
115
Celldex Therapeutics
CLDX
$2.79B
$1.13M 0.07%
+2,132
New +$731K
FCSC
116
DELISTED
Fibrocell Science Inc.
FCSC
$1.1M 0.07%
+16,733
New +$1.35M
TEVA icon
117
Teva Pharmaceuticals
TEVA
$36.9B
$1.08M 0.07%
28,603
+7,867
+38% +$307K
CATX icon
118
Perspective Therapeutics
CATX
$327M
$1.08M 0.07%
+166,310
New +$1.04M
AVNR
119
PUT
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$1.07M 0.07%
+2,534
New +$12K
ALXA
120
CALL
DELISTED
Alexza Pharmaceuticals Inc
ALXA
$1.04M 0.07%
2,040
-10
-0.5% -$47
ARAY icon
121
PUT
Accuray
ARAY
$29M
$1.03M 0.07%
+1,400
New +$8.85K
TMP icon
122
Tompkins Financial
TMP
$1.45B
$1.02M 0.07%
+288,454
New +$13.1M
IRD
123
Opus Genetics
IRD
$282M
$1.01M 0.07%
+4,689
New +$1.09M
SCON
124
DELISTED
Superconductor Technologies Inc.
SCON
$1M 0.07%
+413
New +$1.31M
TCRT icon
125
CALL
Alaunos Therapeutics
TCRT
$4.64M
$972K 0.06%
16
-6
-27% -$2.7K
3 4
5
6 7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2013 Portfolio in Review

As of Q3 2013, Sabby Management held 259 positions worth $1.54B, up 2.7% from $1.5B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sabby Management withdrew a net $337M in Q3 2013, closing 65 positions and reducing 41 holdings. Its most notable exit was AbbVie, an estimated $14.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 11% a quarter earlier, followed by Financials and Technology.

Against the trend, Sabby Management opened a new position in Tompkins Financial worth $1.02M.

  • Sabby Management's largest Q3 2013 buy was Tompkins Financial: 288,454 shares worth $1.02M.
  • Sabby Management added most to Vertex Pharmaceuticals in Q3 2013, an estimated $25.6M increase.
  • Sabby Management's biggest Q3 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $28.4M.
  • Sabby Management fully exited AbbVie in Q3 2013, selling an estimated $14.7M.
  • Sabby Management's ten largest holdings make up 47% of its $1.54B portfolio in Q3 2013.
  • Sabby Management opened 90 new positions and closed 65 in Q3 2013.
  • Sabby Management's portfolio value rose 2.7% quarter-over-quarter to $1.54B.

Based on Sabby Management's 13F filing for Q3 2013, filed 14 Nov 2013.